Reduction of the biomarker survivin/BIRC5 with upregulation of the differentiation antigen CK20 in circulating tumor cells (CTC), strongly correlated with plasma concentrations of drug (R = 0.97) [181], demonstrating on target efficacy. This evidence concerns the gene BIRC5 and neoplasm.